Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed AML
NCT07642453Phase 2Not yet recruiting
- Sponsor
- Hematology Department, 920th Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
01
Overview
Phase 2, randomised trial of venetoclax, azacitidine, cytarabine and filgrastim in acute myeloid leukemia (AML) (2 arms), sponsored by Hematology Department, 920th Hospital. Primary endpoint: Complete Remission rate at 30 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
venetoclaxazacitidinecytarabinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07642453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07642453.